• Français
  • English
  • Nous soutenir

Biotherapy for Innovation in Orphan Disease

Biotherapy for Innovation in Orphan Disease

  • Le Centre
    de Biothérapie
    • Présentation
    • La direction
    • Les missions
    • Les équipes
    • Plan d’accès
  • Les Unités
    de Biothérapie
    • LTCG – Laboratoire de bioproduction
    • UHT – Hôpital de jour
    • UHTI – Thérapies Innovantes
    • CIC-BT – Recherche et développement
  • Essais
    Cliniques
  • Partenaires
    & Financement
    • Partenaires
    • Financement
  • Actualités
    & Publications
    • Actualités
    • Publications scientifiques
  • Parcours
    patient
    • Consultations
    • Hôpital de jour
    • Hospitalisation
    • Lexique
Actualités : Presse, Congrès & Publications scientifiquesPublications scientifiques

Publications scientifiques

Publications scientifiques 1 mars 2026

Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link.

Academic autologous cell manufacturing offers key advantages, including cost-effectiveness, accessibility, and flexibility. However, the management of Raw Materials, Reagents, and Consumables (RMRCs) is essential for ensuring product purity, safety, and effectiveness. Variations in RMRC quality can increase production costs and [...]

Publications scientifiques 1 octobre 2025

Beyond conventional adoptive T-cell therapy.

Reconstitution of the T-cell compartment is essential in the treatment of several immune disorders. Similarly, individuals with hematologic malignancies who are undergoing allogeneic hematopoietic stem cell transplantation experience prolonged T-cell deficiencies, which increase their risk of infections and relapses. Various [...]

Publications scientifiques 1 avril 2025

Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease.

In sickle cell disease (SCD), the β6 substitution in the β-globin leads to red blood cell sickling. The transplantation of autologous, genetically modified hematopoietic stem and progenitor cells (HSPCs) is a promising treatment option for patients with SCD. We completed [...]

Publications scientifiques 5 juillet 2024

Restoration of T and B Cell Differentiation after RAG1 Gene Transfer in Human RAG1 Defective Hematopoietic Stem Cells.

Recombinase-activating gene (RAG)-deficient SCID patients lack B and T lymphocytes due to the inability to rearrange immunoglobulin and T cell receptor genes. The two genes act as a required dimer to initiate gene recombination. Gene therapy is a valid treatment [...]

Publications scientifiques 25 août 2023

Sickle Cell Disease: From Genetics to Curative Approaches.

Sickle cell disease (SCD) is a monogenic blood disease caused by a point mutation in the gene coding for β-globin. The abnormal hemoglobin [sickle hemoglobin (HbS)] polymerizes under low-oxygen conditions and causes red blood cells to sickle. The clinical presentation [...]

Publications scientifiques 21 février 2023

Severe hematopoietic stem cell inflammation compromises chronic granulomatous disease gene therapy.

X-linked chronic granulomatous disease (CGD) is associated with defective phagocytosis, life-threatening infections, and inflammatory complications. We performed a clinical trial of lentivirus-based gene therapy in four patients (NCT02757911). Two patients show stable engraftment and clinical benefits, whereas the other two [...]

Publications scientifiques 1 janvier 2022

A new step in understanding stem cell mobilization in patients with Fanconi anemia: A bridge to gene therapy.

Fanconi anemia (FA) is an inherited disorder characterized clinically by congenital abnormalities, progressive bone marrow failure (BMF), and a predisposition to malignancy. Gene therapy (GT) of FA, via the infusion of gene-corrected peripheral blood (PB) autologous hematopoietic stem cells (HSCs), [...]

Publications scientifiques 1 janvier 2022

Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome.

Patients with Wiskott-Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long-term follow-up results (median follow-up, 7.6 years) (phase I/II trial no. NCT02333760 [...]

Publications scientifiques 1 janvier 2022

Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.

Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are the most prevalent monogenic disorders worldwide. Trial HGB-205 ( NCT02151526 ) aimed at evaluating gene therapy by autologous CD34 cells transduced ex vivo with lentiviral vector BB305 that encodes the anti-sickling [...]

Publications scientifiques 29 avril 2021

A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome.

Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is caused by mutations in forkhead box P3 (FOXP3), which lead to the loss of function of regulatory T cells (Tregs) and the development of autoimmune manifestations early in life. The selective induction of [...]

  • Le Centre
    de Biothérapie
    • Présentation
    • La direction
    • Les missions
    • Les équipes
    • Plan d’accès
  • Les Unités
    de Biothérapie
    • LTCG – Laboratoire de bioproduction
    • UHT – Hôpital de jour
    • UHTI – Thérapies Innovantes
    • CIC-BT – Recherche et développement
  • Essais
    Cliniques
  • Partenaires
    & Financement
    • Partenaires
    • Financement
  • Actualités
    & Publications
    • Actualités
    • Publications scientifiques
  • Parcours
    patient
    • Consultations
    • Hôpital de jour
    • Hospitalisation
    • Lexique
  • Nous rejoindre / carrière
  • Nous soutenir
  • Nous contacter
  • Le Centre de Biothérapie
  • Parcours patient
  • Politique de confidentialité
  • Mentions légales
© copyright 2026 - Hôpital Necker / Institut Imagine / Necker Biotherapy Center